WSF OpenID Connect Login
Therapy areas
Premenstrual dysphoric disorder (PMDD) is the most severe form of PMS, causing distress over a significant period of a woman’s lifetime1-4
PMDD usually comprises distressing physical, psychological and behavioral symptoms1,2
- PMDD can cause distress or even functional impairment over a significant period of a woman’s lifetime1,4
- Women with PMDD face symptoms on a monthly basis from their early 20s until menopause, hence they may be symptomatic for about 2,800 days, or 7–8 years, over their lifetime4
- An estimated 3–8% of women of reproductive age meet the strict criteria for a diagnosis of PMDD3
- The prevalence of clinically relevant PMDD is probably higher (13–18% of women of reproductive age)3
PMDD – premenstrual dysphoric disorder; PMS – premenstrual syndrome
- Mishell DR Jr. Am J Manag Care 2005;11(16):S473–S479. Return to content
- Di Giulio G and Reissing ED. J Psychosom Obstet Gynaecol 2006;27(4):201–210. Return to content
- Halbreich U, Borenstein J, Pearlstein T et al. Psychoneuroendocrinology 2003;28(3):1–23. Return to content
- Yonkers KA, Brown C, Pearlstein TB et al. Obstet Gynecol 2005;106(3):492–501. Return to content
Women diagnosed with PMDD show symptoms of emotional and physical impairment; the latter include fluid-retention symptoms such as breast tenderness and bloating1
YAZ® is the first COC indicated for the treatment of PMDD in women seeking contraception.2
- Women diagnosed with PMDD show symptoms of emotional and physical impairment; the latter include fluid-retention symptoms such as breast tenderness, breast swelling and a bloated sensation1
- YAZ® contains drospirenone which has anti-mineralocorticoid properties, reducing estrogen-induced sodium and fluid retention3
COC – combined oral contraceptive; PMDD – premenstrual dysphoric disorder
- Kessel B. Premenstrual syndrome. Obstet Gynecol Clin North Am 2000;27(3):625–639. Return to content
- Yaz® Summary of Product Characteristics Return to content
- Fuhrmann U, Krattenmacher R, Slater EP, et al. Contraception 1996;54(4):243–251 Return to content
YAZ® effectively reduces the emotional and physical symptoms associated with PMDD in women seeking contraception
Data from two randomized, double-blind, placebo-controlled pivotal studies show that, in women with PMDD seeking contraception, treatment with YAZ® results in statistically significant and clinically meaningful reductions in symptomatology, compared with placebo:1,2
- Treatment with YAZ® significantly improved mood, behavioral, and physical symptoms (including breast tenderness, breast swelling and bloated sensation), compared with placebo treatment, as shown by a marked reduction in the respective symptom scores of the daily record of severity of problems scale1
- Treatment with YAZ® was associated with a significantly greater decrease in the total daily record of severity of problems scale, including physical symptoms (breast tenderness, breast swelling, bloated sensation) from baseline compared to placebo (P<0.001)2
PMDD – premenstrual dysphoric disorder
- Yonkers KA, Brown C, Pearlstein TB et al. Obstet Gynecol 2005;106(3):492–501. Return to content
- Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Contraception 2005;72:414–21. Return to content
Recommendations
